ATE204567T1 - 1,4-dihydropyridine als bradykinin antagonisten - Google Patents

1,4-dihydropyridine als bradykinin antagonisten

Info

Publication number
ATE204567T1
ATE204567T1 AT95918113T AT95918113T ATE204567T1 AT E204567 T1 ATE204567 T1 AT E204567T1 AT 95918113 T AT95918113 T AT 95918113T AT 95918113 T AT95918113 T AT 95918113T AT E204567 T1 ATE204567 T1 AT E204567T1
Authority
AT
Austria
Prior art keywords
pct
dihydropyridines
sec
bradykinine
antagonists
Prior art date
Application number
AT95918113T
Other languages
English (en)
Inventor
Fumitaka Ito
Hiroshi Kondo
David L Hageman
John A Lowe Iii
Susumu Nakanishi
Fredric J Vinick
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE204567T1 publication Critical patent/ATE204567T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT95918113T 1994-08-24 1995-05-26 1,4-dihydropyridine als bradykinin antagonisten ATE204567T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP1994/001398 WO1996006083A1 (en) 1994-08-24 1994-08-24 2-(piperazinyl-1-carbonylmethyl)-1,4-dihydropyridines as bradykinin antagonists
PCT/IB1995/000400 WO1996006082A1 (en) 1994-08-24 1995-05-26 Dihydropyridine derivatives as bradykinin antagonists

Publications (1)

Publication Number Publication Date
ATE204567T1 true ATE204567T1 (de) 2001-09-15

Family

ID=14098614

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95918113T ATE204567T1 (de) 1994-08-24 1995-05-26 1,4-dihydropyridine als bradykinin antagonisten

Country Status (21)

Country Link
US (1) US5859011A (de)
EP (1) EP0777653B1 (de)
JP (1) JP3001978B2 (de)
KR (1) KR100235285B1 (de)
CN (1) CN1087737C (de)
AT (1) ATE204567T1 (de)
AU (1) AU689587B2 (de)
CA (1) CA2198231C (de)
DE (1) DE69522332T2 (de)
DK (1) DK0777653T3 (de)
ES (1) ES2159637T3 (de)
FI (1) FI970745A (de)
GR (1) GR3036907T3 (de)
IL (1) IL114968A (de)
MX (1) MX9701363A (de)
MY (1) MY115372A (de)
NO (1) NO970806L (de)
NZ (1) NZ285155A (de)
TW (1) TW500722B (de)
WO (2) WO1996006083A1 (de)
ZA (1) ZA977057B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TNSN97037A1 (fr) * 1996-02-19 2005-03-15 Pfizer Derives de 1,4 -dihydropyridine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MX9701245A (es) * 1996-02-19 1998-04-30 Pfizer Compuestos de 1,4 dihidropiridina.
JP3823388B2 (ja) * 1996-09-04 2006-09-20 カシオ計算機株式会社 印刷装置
JPH11106375A (ja) * 1997-08-18 1999-04-20 Pfizer Pharmaceut Inc ブラジキニンアンタゴニストとしての光学的に活性な１，４−ジヒドロピリジン化合物
KR100579792B1 (ko) * 1998-05-13 2006-05-12 동화약품공업주식회사 신규 2,5-피리딘디카복실산 유도체
ATE257479T1 (de) * 1999-12-10 2004-01-15 Pfizer 5-ring heteroarylsubstituierte 1,4- dihydropyridine als bradykinin antagonisten
DE60001535T2 (de) * 1999-12-10 2003-10-02 Pfizer Inc., New York Substituierte 1,4-Dihydropyridinverbindungen zur Verwendung als Bradykininantagonisten
EP1110962A1 (de) * 1999-12-10 2001-06-27 Pfizer Inc. Verfahren zur herstellung von 1,4-dihydropyridine verbindungen
US6653313B2 (en) * 2000-08-10 2003-11-25 Warner-Lambert Company Llc 1,4-dihydropyridine compounds as bradykinin antagonists
PT2813502T (pt) 2013-06-14 2017-04-06 Dompé Farm S P A Antagonistas do recetor da bradicinina e composições farmacêuticas que os contêm

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162497A (en) * 1987-09-24 1992-11-10 The Administrators Of The Tulane Educational Fund Bradykinin analogs with non-peptide bond
US5120750A (en) * 1989-01-17 1992-06-09 Synphar Laboratories, Inc. Generation of 1,4-dihydropyridine derivatives
US5610142A (en) * 1992-10-08 1997-03-11 Scios Inc. Bradykinin antagonist pseudopeptide derivatives of substituted 4-keto-1,3,8-triazaspiro[4.5]decan-3-alkanoic acids

Also Published As

Publication number Publication date
CA2198231A1 (en) 1996-02-29
DE69522332T2 (de) 2002-01-03
MX9701363A (es) 1997-05-31
AU2416695A (en) 1996-03-14
IL114968A (en) 1999-08-17
GR3036907T3 (en) 2002-01-31
US5859011A (en) 1999-01-12
WO1996006082A1 (en) 1996-02-29
MY115372A (en) 2003-05-31
CN1087737C (zh) 2002-07-17
JPH09510992A (ja) 1997-11-04
KR100235285B1 (ko) 2000-02-01
FI970745A0 (fi) 1997-02-21
NO970806L (no) 1997-04-21
EP0777653B1 (de) 2001-08-22
FI970745A (fi) 1997-02-21
NZ285155A (en) 1998-06-26
DE69522332D1 (de) 2001-09-27
JP3001978B2 (ja) 2000-01-24
NO970806D0 (no) 1997-02-21
CA2198231C (en) 1999-12-07
TW500722B (en) 2002-09-01
ZA977057B (en) 1997-02-24
ES2159637T3 (es) 2001-10-16
AU689587B2 (en) 1998-04-02
WO1996006083A1 (en) 1996-02-29
EP0777653A1 (de) 1997-06-11
CN1156449A (zh) 1997-08-06
IL114968A0 (en) 1995-12-08
KR970705555A (ko) 1997-10-09
DK0777653T3 (da) 2001-10-08

Similar Documents

Publication Publication Date Title
ES2072627T3 (es) Derivados de piridina y n-oxido de piridina de diarilmetilpiperidinas o piperazinas, composiciones y uso de las mismas.
DE69719778D1 (de) Benzonaphthyridine als bronchialtherapeutika
AP9901442A0 (en) 4-(2-Keto-1-benzimidazolinyl) piperidine compounds as orl1-receptor agonists.
DE69225970D1 (de) Substituierte 2-phenyl-3-methocypropensäurenester als fungizide mittel.
SE9504661D0 (sv) New compounds
ATE204567T1 (de) 1,4-dihydropyridine als bradykinin antagonisten
TR199801268T2 (xx) Ta�ikinin antagonistleri olarak 3-Azetidinilalkilpiperidinler veya pirolidinler.
BR9607335A (pt) Compostos 1-aril-2-acrilamino-etano e seu uso como neuroquinina especialmente antogonistas de neuroquinina 1
DE69227258D1 (de) Neue Endothelin-Antagonisten und ihre Herstellung
DE59510713D1 (de) N-substituierte 3-azabicyclo(3.2.0)heptan-derivate als neuroleptika
IL116526A0 (en) Piperazinediones their preparation and use
DK0775143T3 (da) 3-substituerede 3H-2,3-benzodiazepinderivater, deres fremstilling og anvendelse som lægdemidler
SE9504662D0 (sv) New compounds
SE9402241D0 (sv) Inhibitor
ATE154601T1 (de) 4-amino-2-(hetero)aryl-butanamide verwenbar als 5-ht1a-antagonisten
BR9406765A (pt) N-((1-(4-(4-fluorofenoxi)Butil)-4-Piperidinil)-N-Metilamino)-2-Benzotiazolois como agentes antiarritmicos classe III

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee